BEUDAMED
    FDA Adverse Event Injury Summary report: N

    TERUMO INJECTION FILTER NEEDLE

    MDR report key: 24053285 · Received January 13, 2026

    Report

    Report Number
    9681413-2025-00012
    Event Type
    Injury
    Date Received
    January 13, 2026
    Date of Event
    November 17, 2025
    Report Date
    January 13, 2026
    Manufacturer
    TERUMO EUROPE N.V
    Product Code
    QYM
    UDI-DI
    05413206251223
    PMA / PMN Number
    K230951
    Adverse Event
    Yes
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    SZ
    Reporter Occupation
    003

    Narratives

    Additional Manufacturer Narrative · 0

    D6A: IMPLANTED DATE: DEVICE WAS NOT IMPLANTED. D6B: EXPLANTED DATE: DEVICE WAS NOT EXPLANTED. E3: OCCUPATION: DEVICE QUALITY MANAGER. H6: INVESTIGATION FINDINGS - CODE 3221 IS BASED UPON NO SAMPLE RETURNED; CODE 213 IS BASED UPON FUNCTIONAL TESTING OF THE RETENTION SAMPLE. H6 - INVESTIGATION CONCLUSION - CODE 4315 IS BASED UPON EVALUATION OF USER FACILITY INFORMATION AND NO DEVICE RETURN; CODE 67 IS BASED UPON EVALUATION OF THE RETENTION SAMPLE. THE BATCH RECORDS FOR LOT 2412011 ((B)(6)) HAVE BEEN REVIEWED. THE FOLLOWING TESTS ARE PERFORMED ON THE PRODUCT DURING PRODUCTION: DURING IN-PROCESS CONTROL IN NEEDLE ASSEMBLY, 315 NEEDLES ARE VISUALLY INSPECTED PER SHIFT FOR FOREIGN MATTER. NO ABNORMALITIES RELATED TO THIS COMPLAINT WERE REPORTED DURING THESE INSPECTIONS. DURING IN-PROCESS CONTROL IN PACKAGING, 40 NEEDLES ARE VISUALLY INSPECTED TWICE PER SHIFT FOR FOREIGN MATTER. NO ABNORMALITIES RELATED TO THIS COMPLAINT WERE REPORTED DURING THESE INSPECTIONS. FURTHERMORE, A FINAL VISUAL INSPECTION WAS PERFORMED ON (B)(4) PIECES. TWO (2) PRODUCTS WERE FOUND WITH EMBEDDED DIRT, ONE IN THE HUB AND ONE IN THE PROTECTOR. THIS IS A MINOR DEFECT AND WAS WITHIN THE ACCEPTANCE LEVEL. SINCE THESE PRODUCTS ARE STERILISED AND THE PARTICLES ARE EMBEDDED, IT IS VERY UNLIKELY THAT THIS WOULD CAUSE A PATIENT REACTION. AS PART OF THE FINAL INSPECTION, PARTICULATE MATTER IS TESTED ON (B)(4) PIECES AND A VISUAL INSPECTION ON (B)(4) PIECES. THIS WAS CONFORM THE SPECIFICATION. THE LAL AND STERILIZATION CYCLE WERE EXECUTED ACCORDING TO SPECIFICATION AND NO OBSERVATIONS HAVE BEEN FOUND FOR THESE TESTS. SAMPLE INVESTIGATION: NOT RETURNED. RETENTION SAMPLES: ALL REMAINING SAMPLES ((B)(4) PIECES) WERE VISUALLY INSPECTED FOR FOREIGN MATTER 10/12/2025 BY THE NAKED EYE. NO DEFECTS WERE FOUND. BASED ON OUR INVESTIGATION INCLUDING A BATCH RECORD REVIEW AND RETENTION SAMPLE INVESTIGATION, NO ROOT CAUSE RELATED TO OUR PRODUCTION PROCESS HAS BEEN FOUND. TERUMO MEDICAL PRODUCTS (TMP) (IMPORTER) REGISTRATION NO. 2243441 IS SUBMITTING THIS REPORT ON BEHALF OF TERUMO EUROPE N.V. (MANUFACTURER) REGISTRATION NO. 9681413.

    Description of Event or Problem · 0

    TERUMO MEDICAL CORPORATION RECEIVED THE REPORTED INFORMATION. THE COMPLAINT AFFECTS FILTER NEEDLES CO-PACKED WITH VABYSMO. THE DOCTOR HAD CONCERNS REGARDING THE QUALITY OF VABYSMO PFS. THE DEVICE WAS INVOLVED IN AN IOI CASE. THE DOCTOR HAD NOT REPORTED ANY SPECIFIC PRODUCT QUALITY DEFICIENCY. THE PROCEDURE OUTCOME WAS FINAL PATIENT IMPACT WERE UNKNOWN. ADDITIONAL INFORMATION WAS RECEIVED ON 06JAN2026: IOI IS INTRA-OCULAR INFLAMMATION. IN PARTICULAR, THE PATIENT EXPERIENCED AN UVEITIS. BELOW IS THE EXTRACT OF THE MEDICAL REPORT: ON AN UNKNOWN DATE, THE PATIENT STARTED THERAPY WITH SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE FARICIMAB FOR DIABETIC MACULAR OEDEMA (DMO) EVERY MONTH, IN LEFT EYE TREATMENT WAS ADMINISTERED WITH THE NEEDLE INCLUDED IN THE PACKAGE AND PFS WAS USED FROM THE START WITHOUT PRIOR VIAL USE. DATE OF LAST DOSE PRIOR TO ADVERSE EVENT (AE) ONSET WAS NOT REPORTED. ON AN UNKNOWN DATE, IT WAS REPORTED THAT, SHE HAD FIRST 3 DOSES ON A MONTHLY SCHEDULE, SHE ATTENDED THE CLINIC TO RECEIVE THE 3RD DOSE, DURING THE REVIEW, BEFORE THE ADMINISTRATION OF THE 3RD DOSE, SHE REPORTED THAT SHE EXPERIENCED VISION LOSS AFTER THE ADMINISTRATION OF THE 2ND DOSE ONE MONTH AGO, TOTAL 2 DOSES WERE ADMINISTERED PRIOR TO EVENT, UPON REVIEW, THERE WAS INFLAMMATION IN THE ANTERIOR CHAMBER AND ON AN UNKNOWN DATE, UVEITIS WAS DIAGNOSED. ON AN UNKNOWN DATE, THE PHYSICIAN SUSPECT A QUALITY DEFECT WITH THE BATCH NUMBER (SUSPECTED PRODUCT QUALITY ISSUE). LATER REPORTED THAT, THE ADMINISTRATION OF FARICIMAB IN THIS HOSPITAL WAS CARRIED OUT IN A CLEAN ROOM, UNDER ASEPTIC CONDITIONS, RECOMMENDED NOT TO USE ANY MORE UNITS OF THIS BATCH AT THIS TIME AND REPLACE THEM WITH A NEW BATCH. ON AN UNREPORTED DATE, HER VISION HAD RECOVERED SPONTANEOUSLY AND TREATMENT WITH FARICIMAB WAS STOPPED AND ON AN UNKNOWN DATE, TOPICAL AND ORAL CORTICOSTEROIDS ARE STARTED. ON (B)(6) 2025, VISUAL ACUITY BEFORE THE ONSET OF EVENT WAS 0.5, ON SAME DATE INTRAOCULAR PRESSURE WAS 20 MMHG AND AFTER THE EVENT ON (B)(6) 2025 VISUAL ACUITY WAS 0.5 AND INTRAOCULAR PRESSURE WAS 20 MMHG AND OPTICAL COHERENCE TOMOGRAPHY (OCT) SHOWED ALTERATIONS IN RETINAL PIGMENT EPITHELIUM (RPE), LOW CYSTOID MACULAR OEDEMA (CME). OPHTHALMOLOGICAL EXAMINATION, FLUORESCEIN ANGIOGRAPHY, SLIT LAMP EXAMINATION AND INDIRECT OPHTHALMOSCOPE SHOWED MUTTON-FAT KERATIC PRECIPITATES. NO SAMPLE WAS TAKEN FOR CULTURE AND SENSITIVITY.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    119616 TERUMO INJECTION FILTER NEEDLE OPHTHALMIC NEEDLE QYM TERUMO EUROPE N.V NF-3013RBKE05M 2412011 05413206251223

    Patients

    Seq Age Sex Outcome Treatment
    1 NA Unknown Other SYRINGE (FOR PRODUCT VABYSMO)